# US 2019/0314414 A1 · Materials and methods for engineering cells and uses thereof in immuno-oncology

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314414 A1
- Document ID: US20190314414A1
- Status: Published application
- Kind: A1
- Application number: 16/435,173
- Filed: 2019-06-07
- Published: 2019-10-17
- Earliest claimed: 2017-05-12
- Assignees: Crispr Therapeutics AG
- Applicants: CRISPR Therapeutics AG
- Inventors: Jonathan Alexander TERRETT; Demetrios KALAITZIDIS; Lawrence KLEIN
- Web page: https://patentgrep.com/patent/US20190314414A1

## CPC

- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/4211: {CD19 or B4}
- A61K 40/4213: {CD74, Ii, MHC class II invariant chain or MHC class II gamma chain}
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61K 40/4232: {Tumor necrosis factors [TNF] or CD70}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C12N 5/0634: {Cells from the blood or the immune system}
- C12N 5/0636: {T lymphocytes}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 40/50: characterised by the use of allogeneic cells
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2239/56: Kidney
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.

## Claims

### Claim at position 1

-186. (canceled)

### Claim 187

A population of cells comprising engineered human T cells, wherein the engineered human T cells comprise:
(a) a disrupted T cell receptor alpha chain constant region (TRAC) gene comprising a deletion of the nucleotide sequence of SEQ ID NO: 76, and comprising a nucleic acid encoding a chimeric antigen receptor (CAR) comprising (i) an ectodomain that comprises an anti-BCMA single-chain variable fragment (scFv), wherein the anti-BCMA scFv comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 1524, 1530, or 1589, and a variable light chain comprising the amino acid sequence of SEQ ID NO: 1526, 1527, 1531, or 1590, (ii) a CD8 transmembrane domain, and (iii) an endodomain that comprises a CD28 or 41BB co-stimulatory domain and a CD3z co-stimulatory domain; and
(b) a disrupted beta-2-microglobulin (B2M) gene.

### Claim 188 (depends on 187)

The population of cells of claim 187, wherein the anti-BCMA scFv comprises:
(i) a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 1524 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 1526;
(ii) a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 1524 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 1527;
(iii) a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 1530 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 1531; and
(iv) a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 1589 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 1590.

### Claim 189 (depends on 188)

The population of cells of claim 188, wherein the anti-BCMA scFv comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 1589 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 1590.

### Claim 190 (depends on 189)

The population of cells of claim 189, wherein the CAR comprises an endodomain comprising a 41BB co-stimulatory domain and a CD3z co-stimulatory domain.

### Claim 191 (depends on 187)

The population of cells of claim 187, wherein (i) at least 70% of the engineered human T cells do not express a detectable level of TCR surface protein; (ii) at least 50% of the engineered human T cells do not express a detectable level of B2M surface protein; and/or (iii) at least 50% of the engineered human T cells express a detectable level of the CAR.

### Claim 192 (depends on 187)

The population of cells of claim 187, wherein (i) co-culture of the engineered human T cells with BCMA+ B cells results in lysis of at least 50% of the BCMA+ cells; (ii) the engineered human T cells produce interferon gamma in the presence of BCMA+ cells; and/or (iii) the engineered human T cells do not proliferate in the absence of cytokine stimulation, growth factor stimulation, or antigen stimulation.

### Claim 193 (depends on 187)

The population of cells of claim 187, wherein the disrupted B2M gene comprises an insertion of at least one nucleotide base pair and/or a deletion of at least one nucleotide base pair.

### Claim 194 (depends on 193)

The population of cells of claim 193, wherein the disrupted B2M gene comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO: 1560; SEQ ID NO: 1561; SEQ ID NO: 1562; SEQ ID NO: 1563; SEQ ID NO: 1564; and SEQ ID NO: 1565.

### Claim 195

A population of cells comprising engineered human T cells, wherein the engineered human T cells comprise:
(a) a disrupted TRAC gene comprising a deletion of the nucleotide sequence of SEQ ID NO: 76, and comprising a nucleic acid encoding a CAR comprising (i) an ectodomain that comprises an anti-BCMA scFv, wherein the anti-BCMA scFv comprises the amino acid sequence of SEQ ID NO: 1503, 1504, 1505, 1506, 1509, 1511, 1513, or 1514, (ii) a CD8 transmembrane domain, and (iii) an endodomain that comprises a CD28 or 41BB co-stimulatory domain and a CD3z co-stimulatory domain; and
(b) a disrupted B2M gene.

### Claim 196 (depends on 195)

The population of cells of claim 195, wherein the anti-BCMA scFv comprises the amino acid sequence of SEQ ID NO: 1509.

### Claim 197 (depends on 196)

The population of cells of claim 196, wherein the CAR comprises an endodomain comprising a 41BB co-stimulatory domain and a CD3z co-stimulatory domain.

### Claim 198 (depends on 195)

The population of cells of claim 195, wherein the anti-BCMA scFv is encoded by the nucleotide sequence of SEQ ID NO: 1479, 1480, 1481, 1482, 1485, 1487, 1489, or 1490.

### Claim 199 (depends on 198)

The population of cells of claim 198, wherein the anti-BCMA scFv is encoded by the nucleotide sequence of SEQ ID NO: 1485.

### Claim 200 (depends on 195)

The population of cells of claim 195, wherein (i) at least 70% of the engineered human T cells do not express a detectable level of TCR surface protein; (ii) at least 50% of the engineered human T cells do not express a detectable level of B2M surface protein; and/or (iii) at least 50% of the engineered human T cells express a detectable level of the CAR.

### Claim 201 (depends on 195)

The population of cells of claim 195, wherein (i) co-culture of the engineered human T cells with BCMA+ B cells results in lysis of at least 50% of the BCMA+ B cells; (ii) the engineered human T cells produce interferon gamma in the presence of BCMA+ cells; and/or (iii) the engineered human T cells do not proliferate in the absence of cytokine stimulation, growth factor stimulation, or antigen stimulation.

### Claim 202 (depends on 195)

The population of cells of claim 195, wherein the disrupted B2M gene comprises an insertion of at least one nucleotide base pair and/or a deletion of at least one nucleotide base pair.

### Claim 203 (depends on 202)

The population of cells of claim 202, wherein the disrupted B2M gene comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO: 1560; SEQ ID NO: 1561; SEQ ID NO: 1562; SEQ ID NO: 1563; SEQ ID NO: 1564; and SEQ ID NO: 1565.

### Claim 204

A population of cells comprising engineered human T cells, wherein the engineered human T cells comprise:
(a) a disrupted TRAC gene comprising a deletion of the nucleotide sequence of SEQ ID NO: 76, and comprising a nucleic acid encoding a CAR, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 1453, 1454, 1455, 1456, 1457, 1460, 1461, 1463, 1465, or 1466; and
(b) a disrupted B2M gene.

### Claim 205 (depends on 204)

The population of cells of claim 204, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 1460.

### Claim 206 (depends on 204)

The population of cells of claim 204, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 1461.

### Claim 207 (depends on 204)

The population of cells of claim 204, wherein the CAR is encoded by the nucleotide sequence of SEQ ID NO: 1427, 1428, 1429, 1430, 1431, 1434, 1435, 1437, 1439, or 1440.

### Claim 208 (depends on 207)

The population of cells of claim 207, wherein the CAR is encoded by the nucleotide sequence of SEQ ID NO: 1435.

### Claim 209 (depends on 204)

The population of cells of claim 204, wherein (i) at least 70% of the engineered human T cells do not express a detectable level of TCR surface protein; (ii) at least 50% of the engineered human T cells do not express a detectable level of B2M surface protein; and/or (iii) at least 50% of the engineered human T cells express a detectable level of the CAR.

### Claim 210 (depends on 204)

The population of cells of claim 204, wherein (i) co-culture of the engineered human T cells with BCMA+ B cells results in lysis of at least 50% of the BCMA+ B cells; (ii) the engineered human T cells produce interferon gamma in the presence of BCMA+ cells; and/or (iii) the engineered human T cells do not proliferate in the absence of cytokine stimulation, growth factor stimulation, or antigen stimulation.

### Claim 211 (depends on 204)

The population of cells of claim 204, wherein the disrupted B2M gene comprises an insertion of at least one nucleotide base pair and/or a deletion of at least one nucleotide base pair.

### Claim 212 (depends on 211)

The population of cells of claim 211, wherein the disrupted B2M gene comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO: 1560; SEQ ID NO: 1561; SEQ ID NO: 1562; SEQ ID NO: 1563; SEQ ID NO: 1564; and SEQ ID NO: 1565.

### Claim 213 (depends on 187)

A composition comprising the population of cells of claim 187, and a pharmaceutically acceptable carrier.

### Claim 214 (depends on 195)

A composition comprising the population of cells of claim 195, and a pharmaceutically acceptable carrier.

### Claim 215 (depends on 204)

A composition comprising the population of cells of claim 204, and a pharmaceutically acceptable carrier.

### Claim 216

A method for producing an engineered human T cell, the method comprising delivering to a human T cell:
(a) a RNA-guided nuclease;
(b) a gRNA targeting a TRAC gene;
(c) a gRNA targeting a B2M gene; and
(d) a vector comprising a nucleic acid comprising (i) a nucleotide sequence that comprises a left region of homology to the TRAC locus, (ii) a nucleotide sequence encoding an anti-BCMA CAR, and (iii) a nucleotide sequence that comprises a right region of homology to the TRAC gene locus,
thereby producing an engineered human T cell.
